The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Statin Use Tied to Attenuation of Tocilizumab-Mediated Lipid Increases

Statin Use Tied to Attenuation of Tocilizumab-Mediated Lipid Increases

December 16, 2016 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Statin treatment is associated with an attenuation of the increases in serum lipids experienced by rheumatoid arthritis patients on tocilizumab, according to a post-hoc analysis of clinical trials.

You Might Also Like
  • Statin Use Tied to Lower Risk of Inflammatory Bowel Disease
  • Lipids, Statin Treatment Linked to Revision Rate After Rotator Cuff Repair
  • Statin Guideline Eliminates Cholesterol Treat-to-Target Strategy for Managing Atherosclerotic Cardiovascular Risk
Also By This Author
  • Trump Backs House Healthcare Plan, Says Open to Negotiations

Treatment with the interleukin-6 receptor-alpha inhibitor tocilizumab is known to raise total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglyceride levels.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

To explore the possible effect of statin treatment, Dr. Martin Soubrier from Universitaire de Clermont-Ferrand in France and colleagues analyzed data from seven international trials on 4,655 patients with rheumatoid arthritis who were treated with tocilizumab.

Most patients (84.8%) did not start statins during the study period, 9.5% were on concomitant statins at baseline, and 5.9% began to take the drugs during the study, the researchers report in Rheumatology and Therapy, online November 29.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Statin use at baseline was associated with the smallest increase in LDL-cholesterol over the first three to four months of tocilizumab treatment, whereas the initiation of treatment with statins was associated with the greatest increase in LDL-cholesterol over this time.

Between 24.8% and 31.8% (depending on tocilizumab dosing and combinations) of patients who were on statins at baseline experienced an increase in LDL-cholesterol from <130 mg/dL at baseline to >= 130 mg/dL at three to four months. This compared with 53.3% to 73.3% of those who initiated statins post-baseline and 36.7% to 42.4% of those who never initiated statins.

After the first three to four months, LDL-cholesterol varied little among patients on statins at baseline and among patients untreated with statins at any point, whereas LDL-cholesterol levels decreased gradually among patients who initiated statin therapy post-baseline.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Similar trends were observed for total cholesterol, HDL-cholesterol, and triglycerides.

At two years, about 78% of patients on intravenous tocilizumab had LDL-cholesterol >=100 mg/dL, but only 11.0% of those receiving tocilizumab monotherapy and 13.3% of those receiving tocilizumab combination therapy were taking statins.

“Tocilizumab is known to reduce chronic inflammation, and these results suggest that concomitant treatment with statins may attenuate lipid increases with tocilizumab treatment,” the researchers conclude.

“Taken together, these findings highlight the need for better understanding of potential risk associated with tocilizumab-mediated lipid elevations as well as development and implementation of rheumatoid arthritis-specific guidelines on the recognition and management of elevated risk of cardiovascular events in patients with rheumatoid arthritis,” they add.

Hoffman-La Roche, Ltd. funded this study, employed two of the four authors (at Genentech, Inc.), and provided honoraria for one of the other authors.

Dr. Soubrier did not respond to a request for comments.

Pages: 1 2 | Single Page

Filed Under: Drug Updates, Rheumatoid Arthritis Tagged With: RA, Rheumatoid arthritis, serum lipids, statin treatment, tocilizumab

You Might Also Like:
  • Statin Use Tied to Lower Risk of Inflammatory Bowel Disease
  • Lipids, Statin Treatment Linked to Revision Rate After Rotator Cuff Repair
  • Statin Guideline Eliminates Cholesterol Treat-to-Target Strategy for Managing Atherosclerotic Cardiovascular Risk
  • Cardiovascular Risk in Tocilizumab Therapy for RA

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)